Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03676647 · ClinicalTrials.gov registry record
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
A clinical trial of Thyroid Gland Nodule, sponsored by City of Hope Medical Center.
- Recruiting
- Registry status
- 22
- Enrollment target
- 1
- Study location
NCT03676647 is a study of Thyroid Gland Nodule that is actively recruiting participants, run by City of Hope Medical Center. The registered enrollment target is 22 participants. The trial reports 1 study location across 1 state.
The verdict
NCT03676647, a study of Thyroid Gland Nodule, is actively recruiting participants, sponsored by City of Hope Medical Center.
- RECRUITING
- Registry status
- 22 participants
- Enrollment target
- 1
- Study location
Study Summary
This trial studies how well the diagnostic deoxyribonucleic acid (DNA) methylation signature works in detecting thyroid cancer in patients with thyroid nodules. Using diagnostic testing, such as the diagnostic DNA methylation signature, may be a less invasive way to check for thyroid cancer.
Conditions Studied
Interventions
- OTHER Diagnostic DNA Methylation Signature
Study Locations (1)
California
- City of Hope Medical Center - Duarte
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2026-04-25 |
| Est. Completion | 2028-09-25 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03676647
The ClinicalTrials.gov registry entry for NCT03676647 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Thyroid Gland Nodule appearing as the primary indexed condition, and to 1 intervention - of which Diagnostic DNA Methylation Signature is the first listed.
NCT03676647 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT03676647 about?
NCT03676647 is a clinical study titled "Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules". This trial studies how well the diagnostic deoxyribonucleic acid (DNA) methylation signature works in detecting thyroid cancer in patients with thyroid nodules. Using diagnostic testing, such as the diagnostic DNA methylation signature, may be a less invasive way to check for thyroid cancer.
What is the current status of trial NCT03676647?
This trial is currently recruiting. The enrollment target is 22 participants. The study started on 2026-04-25. Estimated completion is 2028-09-25.
What conditions does trial NCT03676647 study?
This clinical trial studies the following conditions: Thyroid Gland Nodule.
What interventions are being tested in trial NCT03676647?
The interventions under investigation include: Diagnostic DNA Methylation Signature (OTHER).
Who is sponsoring clinical trial NCT03676647?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03676647 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Thyroid Gland Nodule
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.